120 related articles for article (PubMed ID: 9315094)
1. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity.
Kondo T; Minamino N; Nagamura-Inoue T; Matsumoto M; Taniguchi T; Tanaka N
Oncogene; 1997 Sep; 15(11):1275-81. PubMed ID: 9315094
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain.
Nguyen H; Mustafa A; Hiscott J; Lin R
Oncogene; 1995 Aug; 11(3):537-44. PubMed ID: 7630638
[TBL] [Abstract][Full Text] [Related]
3. [Identification and analysis of IRF-1 binding protein].
Kondo T
Hokkaido Igaku Zasshi; 1996 Jul; 71(4):509-16. PubMed ID: 8809574
[TBL] [Abstract][Full Text] [Related]
4. The interferon regulatory factors 1 and 2 bind to a segment of the human c-myb first intron: possible role in the regulation of c-myb expression.
Manzella L; Gualdi R; Perrotti D; Nicolaides NC; Girlando G; Giuffrida MA; Messina A; Calabretta B
Exp Cell Res; 2000 Apr; 256(1):248-56. PubMed ID: 10739671
[TBL] [Abstract][Full Text] [Related]
5. Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression.
Tan RS; Taniguchi T; Harada H
Cancer Res; 1996 May; 56(10):2417-21. PubMed ID: 8625321
[TBL] [Abstract][Full Text] [Related]
6. Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q- associated leukemias.
Beretta L; Gabbay M; Berger R; Hanash SM; Sonenberg N
Oncogene; 1996 Apr; 12(7):1593-6. PubMed ID: 8622878
[TBL] [Abstract][Full Text] [Related]
7. Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors.
Lee AH; Hong JH; Seo YS
Biochem J; 2000 Aug; 350 Pt 1(Pt 1):131-8. PubMed ID: 10926836
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma regulation of the human mimecan promoter.
Tasheva ES; Conrad GW
Mol Vis; 2003 Jun; 9():277-87. PubMed ID: 12835654
[TBL] [Abstract][Full Text] [Related]
9. Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation.
Nguyen H; Teskey L; Lin R; Hiscott J
Oncogene; 1999 Sep; 18(39):5455-63. PubMed ID: 10498899
[TBL] [Abstract][Full Text] [Related]
10. Induction of transcription factor interferon regulatory factor-1 by interferon-gamma (IFN gamma) and tumor necrosis factor-alpha (TNF alpha) in FRTL-5 cells.
Mori K; Stone S; Khaodhiar L; Braverman LE; DeVito WJ
J Cell Biochem; 1999 Aug; 74(2):211-9. PubMed ID: 10404391
[TBL] [Abstract][Full Text] [Related]
11. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2.
Xi H; Eason DD; Ghosh D; Dovhey S; Wright KL; Blanck G
Oncogene; 1999 Oct; 18(43):5889-903. PubMed ID: 10557076
[TBL] [Abstract][Full Text] [Related]
12. Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis.
Kirchhoff S; Hauser H
Oncogene; 1999 Jun; 18(25):3725-36. PubMed ID: 10391680
[TBL] [Abstract][Full Text] [Related]
13. Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins.
Nguyen H; Lin R; Hiscott J
Oncogene; 1997 Sep; 15(12):1425-35. PubMed ID: 9333018
[TBL] [Abstract][Full Text] [Related]
14. IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo.
Kröger A; Dallügge A; Kirchhoff S; Hauser H
Oncogene; 2003 Feb; 22(7):1045-56. PubMed ID: 12592391
[TBL] [Abstract][Full Text] [Related]
15. Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors.
Meraro D; Hashmueli S; Koren B; Azriel A; Oumard A; Kirchhoff S; Hauser H; Nagulapalli S; Atchison ML; Levi BZ
J Immunol; 1999 Dec; 163(12):6468-78. PubMed ID: 10586038
[TBL] [Abstract][Full Text] [Related]
16. MNDA binds NPM/B23 and the NPM-MLF1 chimera generated by the t(3;5) associated with myelodysplastic syndrome and acute myeloid leukemia.
Xie J; Briggs JA; Morris SW; Olson MO; Kinney MC; Briggs RC
Exp Hematol; 1997 Oct; 25(11):1111-7. PubMed ID: 9328447
[TBL] [Abstract][Full Text] [Related]
17. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin.
Pizzoferrato E; Liu Y; Gambotto A; Armstrong MJ; Stang MT; Gooding WE; Alber SM; Shand SH; Watkins SC; Storkus WJ; Yim JH
Cancer Res; 2004 Nov; 64(22):8381-8. PubMed ID: 15548708
[TBL] [Abstract][Full Text] [Related]
18. The role of the interferon regulatory factors, IRF-1 and IRF-2, in LPS-induced cyclooxygenase-2 (COX-2) expression in vivo and in vitro.
Zhang S; Thomas K; Blanco JC; Salkowski CA; Vogel SN
J Endotoxin Res; 2002; 8(5):379-88. PubMed ID: 12537697
[TBL] [Abstract][Full Text] [Related]
19. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation.
Harada H; Kondo T; Ogawa S; Tamura T; Kitagawa M; Tanaka N; Lamphier MS; Hirai H; Taniguchi T
Oncogene; 1994 Nov; 9(11):3313-20. PubMed ID: 7936656
[TBL] [Abstract][Full Text] [Related]
20. SUMOylated IRF-1 shows oncogenic potential by mimicking IRF-2.
Park SM; Chae M; Kim BK; Seo T; Jang IS; Choi JS; Kim IC; Lee JH; Park J
Biochem Biophys Res Commun; 2010 Jan; 391(1):926-30. PubMed ID: 19962964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
